BenzingaOctober 19, 2026 at 8:33 AM NY8 Days Ago
Guggenheim Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $44
Guggenheim analyst Seamus Fernandez maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $38 to $44.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
